Drug Type Molecular glue |
Synonyms MRG-001(Medregen), MRG001(Medregen) |
Mechanism BMPR2 modulators(Bone morphogenetic protein receptor type-2 modulators), CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists), CaN inhibitors(Calcineurin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H71NO13 |
InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N |
CAS Registry109581-93-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Phase 2 | - | 01 Jul 2025 | |
Cytokine Release Syndrome | Phase 2 | - | 01 Dec 2024 | |
Respiratory Failure | Phase 2 | - | 01 Dec 2024 | |
Hepatitis, Alcoholic | Phase 2 | - | 01 Sep 2024 | |
Cicatrix | Phase 2 | US | 20 Nov 2023 | |
Wounds and Injuries | Phase 2 | US | 20 Nov 2023 | |
COVID-19 | Phase 2 | US | 01 Dec 2021 | |
Respiratory Distress Syndrome, Acute | Phase 2 | US | 01 Dec 2021 | |
Burns | Phase 1 | US | 11 Mar 2024 | |
Inflammatory Bowel Diseases | Phase 1 | US | 11 Mar 2024 |